retatrutide peptide glp 3 GLP-3 Retatrutide (12mg vials) -

This will likely impact this market, but with the potential upside that BMI reductions due to GLP-1s may take more patients into the indicated weight range for bariatric devices

T2D, non-alcoholic fatty liver disease (also known as metabolic dysfunction-associated steatotic liver disease) and hypertension diagnoses were all associated with lower weight loss efficacy, consistent with previous reports 22,23,24

Figure 1 Incretin action plays a large role on post-prandial secretion of insulin, and may account for up to 70% of hormone release (6)

Don't start a multi-month compounded GLP-1 program without understanding the FDA's pending rule and what it might mean for your supply continuity